Skip to content

Investors Overview

Esperion is a pharmaceutical company passionately committed to developing and commercializing non-statin, once-daily, oral therapies to lower elevated low-density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies. Bempedoic acid is being developed as a once-daily, oral inhibitor of ATP Citrate Lyase (ACL), and is designed to bring a targeted mechanism of action to address patients’ unmet medical needs.

Esperion has been a publicly traded company since 2013 and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Esperion Therapeutics () on
Last Price Change open Day High 52-Week High
Volume Previous Close Day Low 52-Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

Date Title and Summary
Toggle Summary ESPERION Reports Second Quarter 2021 Financial Results and Provides Company Update
– U.S. Net Product Revenue of NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ® (bempedoic acid and ezetimibe) Tablets Grew 67% Sequentially to $10.6 Million – –  Growth Driven by Increase in Demand and Substantial Improvement in Net Price – –  Prescriptions Grew 28% During the Quarter; More Than
Toggle Summary Esperion to Participate in Upcoming Virtual Investor Conference
ANN ARBOR, Mich., July 27, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer of Esperion will participate in the upcoming BTIG Virtual Biotechnology Conference. Event: BTIG Virtual Biotechnology Conference Date: August 9,
Toggle Summary Esperion to Report Second Quarter 2021 Financial Results August 3, 2021
ANN ARBOR, Mich., July 13, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report second quarter 2021 financial results before the open of the U.S. financial markets on Tuesday, August 3, 2021. Following the release, company management will host a webcast and conference
Toggle Summary Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., July 01, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on June 28, 2021, the Compensation Committee of Esperion’s Board of Directors granted 31 new employees (i) non-qualified stock options to purchase an aggregate of 88,692 shares of its common stock, all
Toggle Summary ESPERION Appoints JoAnne Micale Foody, MD, FACC, FAHA as Chief Medical Officer
– Expansion of management team with proven leader in cardiovascular disease supports advancement of CLEAR Outcomes trial and ESPERION therapeutic pipeline – ANN ARBOR, Mich., June 28, 2021 (GLOBE NEWSWIRE) -- ESPERION (NASDAQ: ESPR), today announced the appointment of JoAnne Micale Foody, MD, FACC,
Load More